Masahiro Tsuboi

15PUBLICATIONS
103CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Digital writingTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Dec 19, 2025
Reply to: "NeoADAURA: Can We Afford to Overlook Objective Response Rates?" and "Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?"

Jamie E Chaft, Masahiro Tsuboi, Walter Weder

|Jun 02, 2025
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.

Jianxing He, Masahiro Tsuboi, Walter Weder

|Oct 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).

Keiju Aokage, Shohei Koyama, Shogo Kumagai

|Sep 29, 2023
Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma.

Sho Tabata, Shigeki Umemura, Miyu Narita

|Sep 01, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.

Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi

|Jun 30, 2023
Reply to D. Wu et al.

Roy S Herbst, Yi-Long Wu, Masahiro Tsuboi

Pageof 3

Frequent Collaborators

4 joint publications

Genichiro Ishii

3 joint publications

Yi-Long Wu

3 joint publications

Shohei Koyama

3 joint publications

Hiroyoshi Nishikawa